Septerna
Update in progressSEPN (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Septerna, Inc. is a clinical‑stage biotech company that discovers and develops oral small‑molecule GPCR therapies for endocrinology, immunology/inflammation, and metabolic diseases. Programs include PTH1R agonists for hypoparathyroidism; SEP‑631, a MRGPRX2 NAM for chronic spontaneous urticaria and mast cell diseases; and a TSHR NAM for Graves’ disease and thyroid eye disease. It also explores neurology, women’s health, cardiovascular and respiratory areas. It has a global collaboration with Novo Nordisk for metabolic targets. Formerly GPCR NewCo, it renamed to Septerna in 2021 and is based in South San Francisco, CA.
Company score
- Sentiment
- 0.25
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.06
- Governance
- 0.03
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.03
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.14
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGM (NGM)
- LocationUnited States
- CEODr. Jeffrey T. Finer M.D., Ph.D.
- Founded2019
- Employees123
- Websitesepterna.com
Identifiers
- ISINUS81734D1046
- FIGIBBG014WY1V28